Wang Sheng-Lan, Wang Zhi-Rong, Yang Chang-Qing
Division of Gastroenterology and Digestive Diseases Institute, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, P.R. China.
Exp Ther Med. 2012 Dec;4(6):1051-1056. doi: 10.3892/etm.2012.718. Epub 2012 Sep 20.
Patients with Crohn's disease (CD) or ulcerative colitis (UC) undergo various therapies, including antibiotic therapy. This meta-analysis of controlled clinical trials was conducted to evaluate whether the use of antibacterial therapy improves the clinical symptoms of inflammatory bowel disease (IBD). The Medline and Scopus databases were searched and a systematic review was performed. Randomized, controlled trials in which antibiotic therapy was compared with placebo were investigated. A total of 10 randomized, placebo-controlled clinical trials for CD were included in the meta-analysis. The pooling of the data from these trials yielded an odds ratio (OR) of 1.35 [95% confidence interval (CI), 1.16-1.58] for antibiotic therapy compared with placebo in patients with CD. Furthermore, nine randomized placebo-controlled clinical trials for UC matched our criteria and were included in the analysis. The pooling of the data from these trials yielded an OR of 2.17 (95% CI, 1.54-3.05) in favor of antibiotic therapy. These results suggest that antibiotics improve clinical outcomes in patients with IBD.
患有克罗恩病(CD)或溃疡性结肠炎(UC)的患者会接受包括抗生素治疗在内的各种疗法。本对照临床试验的荟萃分析旨在评估抗菌治疗的使用是否能改善炎症性肠病(IBD)的临床症状。检索了Medline和Scopus数据库并进行了系统评价。对将抗生素治疗与安慰剂进行比较的随机对照试验进行了研究。荟萃分析共纳入了10项针对CD的随机、安慰剂对照临床试验。这些试验数据的汇总得出,CD患者中抗生素治疗与安慰剂相比的优势比(OR)为1.35 [95%置信区间(CI),1.16 - 1.58]。此外,9项符合我们标准的针对UC的随机安慰剂对照临床试验被纳入分析。这些试验数据的汇总得出支持抗生素治疗的OR为2.17(95% CI,1.54 - 3.05)。这些结果表明抗生素可改善IBD患者的临床结局。